These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 15619641)

  • 1. Steroid receptor status, proliferation and metallothionein expression in primary invasive ductal breast cancers.
    Surowiak P; Paluchowski P; Wysocka T; Wojnar A; Zabel M
    Pathol Oncol Res; 2004; 10(4):207-11. PubMed ID: 15619641
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation between metallothionein (MT) expression and selected prognostic factors in ductal breast cancers.
    Gomulkiewicz A; Podhorska-Okolow M; Szulc R; Smorag Z; Wojnar A; Zabel M; Dziegiel P
    Folia Histochem Cytobiol; 2010 Jan; 48(2):242-8. PubMed ID: 20675281
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lack of relationship between metallothionein (MT) expression and proliferation exponents in cells of primary ductal breast cancer of G2 grade of differentiation.
    Surowiak P; Paluchowski P; Dziegiel P; Wysocka T; Wojnar A; Spaczyński M; Zabel M
    Med Sci Monit; 2004 Aug; 10(8):BR300-5. PubMed ID: 15277992
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differences in oestrogen and progesterone receptors, HER-2, p53 expression and proliferation in ductal breast cancers in relation to histopathological grade.
    Zasławski R; Surowiak P; Paluchowski P; Dziegiel P; Maciejczyk A; Pudełko M; Wojnar A; Zabel M
    Folia Morphol (Warsz); 2005 Feb; 64(1):9-15. PubMed ID: 15832264
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elevated metallothionein (MT) expression in invasive ductal breast cancers predicts tamoxifen resistance.
    Surowiak P; Matkowski R; Materna V; Györffy B; Wojnar A; Pudelko M; Dziegiel P; Kornafel J; Zabel M
    Histol Histopathol; 2005 Oct; 20(4):1037-44. PubMed ID: 16136485
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive value and clinical utility of centrally assessed ER, PgR, and Ki-67 to select adjuvant endocrine therapy for premenopausal women with hormone receptor-positive, HER2-negative early breast cancer: TEXT and SOFT trials.
    Regan MM; Pagani O; Francis PA; Fleming GF; Walley BA; Kammler R; Dell'Orto P; Russo L; Szőke J; Doimi F; Villani L; Pizzolitto S; Öhlschlegel C; Sessa F; Peg Cámara V; Rodríguez Peralto JL; MacGrogan G; Colleoni M; Goldhirsch A; Price KN; Coates AS; Gelber RD; Viale G;
    Breast Cancer Res Treat; 2015 Nov; 154(2):275-86. PubMed ID: 26493064
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High Ki-67 Expression and Low Progesterone Receptor Expression Could Independently Lead to a Worse Prognosis for Postmenopausal Patients With Estrogen Receptor-Positive and HER2-Negative Breast Cancer.
    Nishimukai A; Yagi T; Yanai A; Miyagawa Y; Enomoto Y; Murase K; Imamura M; Takatsuka Y; Sakita I; Hatada T; Miyoshi Y
    Clin Breast Cancer; 2015 Jun; 15(3):204-11. PubMed ID: 25600243
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in the ER, PgR, HER2, p53 and Ki-67 biological markers between primary and recurrent breast cancer: discordance rates and prognosis.
    Nishimura R; Osako T; Okumura Y; Tashima R; Toyozumi Y; Arima N
    World J Surg Oncol; 2011 Oct; 9():131. PubMed ID: 22004841
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma.
    Tsutsumi Y
    Jpn J Clin Oncol; 2012 May; 42(5):375-86. PubMed ID: 22450930
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alterations of estrogen receptors, progesterone receptors and c-erbB2 oncogene protein expression in ductal carcinomas of the breast.
    Hussein MR; Abd-Elwahed SR; Abdulwahed AR
    Cell Biol Int; 2008 Jun; 32(6):698-707. PubMed ID: 18296077
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of immunohistochemistry with PCR for assessment of ER, PR, and Ki-67 and prediction of pathological complete response in breast cancer.
    Sinn HP; Schneeweiss A; Keller M; Schlombs K; Laible M; Seitz J; Lakis S; Veltrup E; Altevogt P; Eidt S; Wirtz RM; Marmé F
    BMC Cancer; 2017 Feb; 17(1):124. PubMed ID: 28193205
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic Significance of Single Progesterone Receptor Positivity: A Comparison Study of Estrogen Receptor Negative/Progesterone Receptor Positive/Her2 Negative Primary Breast Cancer With Triple Negative Breast Cancer.
    Fan Y; Ding X; Xu B; Ma F; Yuan P; Wang J; Zhang P; Li Q; Luo Y
    Medicine (Baltimore); 2015 Nov; 94(46):e2066. PubMed ID: 26579819
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunohistochemical localization of metallothionein in human breast cancer in comparison with cathepsin D, stromelysin-1, CD44, extracellular matrix components, P53, Rb, C-erbB-2, EGFR, steroid receptor content and proliferation.
    Ioachim E; Kamina S; Demou A; Kontostolis M; Lolis D; Agnantis NJ
    Anticancer Res; 1999; 19(3A):2133-9. PubMed ID: 10470161
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differentiated expression of estrogen receptors (ER) and progesterone receptors (PgR) in ductal breast cancers.
    Wojnar A; Drozdz K; Podhorska-Okołów M; Pudełko M; Szuba A; Zabel M; Dziegiel P
    Folia Histochem Cytobiol; 2009; 47(1):55-60. PubMed ID: 19419938
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Distribution of Ki-67 values within HER2 & ER/PgR expression variants of ductal breast cancers as a potential link between IHC features and breast cancer biology.
    Kurbel S; Dmitrović B; Marjanović K; Vrbanec D; Juretić A
    BMC Cancer; 2017 Mar; 17(1):231. PubMed ID: 28356061
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discordance of hormone receptor, human epidermal growth factor receptor-2, and Ki-67 between primary breast cancer and synchronous axillary lymph node metastasis.
    Kinoe H; Yamanouchi K; Kuba S; Morita M; Sakimura C; Kanetaka K; Takatsuki M; Abe K; Yano H; Matsumoto M; Otsubo R; Hayashida N; Nagayasu T; Eguchi S
    J BUON; 2018 Dec; 23(7):60-66. PubMed ID: 30722113
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histological grade provides significant prognostic information in addition to breast cancer subtypes defined according to St Gallen 2013.
    Ehinger A; Malmström P; Bendahl PO; Elston CW; Falck AK; Forsare C; Grabau D; Rydén L; Stål O; Fernö M;
    Acta Oncol; 2017 Jan; 56(1):68-74. PubMed ID: 27762648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of ER, PgR, HER-2, and Ki-67 in core biopsies and in definitive histological specimens in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy.
    Rossi L; Verrico M; Tomao S; Ricci F; Fontana A; Spinelli GP; Colonna M; Vici P; Tomao F
    Cancer Chemother Pharmacol; 2020 Jan; 85(1):105-111. PubMed ID: 31754747
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pattern of distribution of cells positive for estrogen receptor alpha and progesterone receptor in relation to proliferating cells in the mammary gland.
    Russo J; Ao X; Grill C; Russo IH
    Breast Cancer Res Treat; 1999 Feb; 53(3):217-27. PubMed ID: 10369068
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Power of PgR expression as a prognostic factor for ER-positive/HER2-negative breast cancer patients at intermediate risk classified by the Ki67 labeling index.
    Kurozumi S; Matsumoto H; Hayashi Y; Tozuka K; Inoue K; Horiguchi J; Takeyoshi I; Oyama T; Kurosumi M
    BMC Cancer; 2017 May; 17(1):354. PubMed ID: 28532429
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.